Announcements Trials
Browse Landscape

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 31Observational 5Expanded_access 1

Sponsor

Cancer Type

Genitourinary 5Thoracic 2Gastrointestinal 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 5Carcinoma, Transitional Cell 5Neoplasms 4Melanoma 3Lung Neoplasms 3Breast Neoplasms 2Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Sarcopenia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

atezolizumab 5avelumab 4erdafitinib 1enfortumab vedotin 1darolutamide 1Therapeutics 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Radiotherapy 1Patient Reported Outcome Measures 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1Laparoscopy 1Immunotherapy 1Histocompatibility Testing 1High-Throughput Nucleotide Sequencing 1Hematologic Tests 1Gemcitabine 1Focus Groups 1Educational Status 1Drug Therapy 1Defecation 1Cytological Techniques 1Cystoscopy 1Cisplatin 1Carboxylesterase 1Blood Cell Count 1Biomarkers 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × Carcinoma, Transitional Cell × atezolizumab × Clear all
NCT03782207 2026-01-08

IMreal

Hoffmann-La Roche

Active not recruiting
2,756 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT06169904 2023-12-14

B7-Family Score in Urothelial Carcinoma

Shanghai Zhongshan Hospital

Completed
215 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03330886 2023-03-13

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Hoffmann-La Roche

Completed
13 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Hoffmann-La Roche

Completed
1,758 enrolled
BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03399643 2019-04-19

Announce

Hoffmann-La Roche

Terminated
22 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡